Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review

Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review

Lung cancer is one of main causes of cancer mortality and 83% of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Patients with NSCLC usually have a poor prognosis and one of the leading causes is drug resistance. With the progress of drug therapy, the emergence and developmen...

Full description

Bibliographic Details
Main Authors: Ruizheng Sun, Ranran Wang, Siyuan Chang, Kexin Li, Rongsi Sun, Mengnan Wang, Zheng Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Pharmacology
Subjects:
long non-coding RNAs
drug resistance
non-small cell lung cancer
cisplatin
taxanes
epidermal growth factor receptor tyrosine kinase inhibitors
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01457/full
Description
Summary:Lung cancer is one of main causes of cancer mortality and 83% of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Patients with NSCLC usually have a poor prognosis and one of the leading causes is drug resistance. With the progress of drug therapy, the emergence and development of drug resistance affected the prognosis of patients severely. Accumulating evidence reveals that long non-coding RNAs (lncRNAs), as “dark matters” of the human genome, is of great significance to drug resistance in NSCLC. Herein, we review the role of lncRNAs in drug resistance in NSCLC.
ISSN:1663-9812

Similar Items